MX361870B - Derivado de piridina monociclico. - Google Patents
Derivado de piridina monociclico.Info
- Publication number
- MX361870B MX361870B MX2015010698A MX2015010698A MX361870B MX 361870 B MX361870 B MX 361870B MX 2015010698 A MX2015010698 A MX 2015010698A MX 2015010698 A MX2015010698 A MX 2015010698A MX 361870 B MX361870 B MX 361870B
- Authority
- MX
- Mexico
- Prior art keywords
- group
- hydrogen atom
- atom
- alkyl group
- nitrogenated
- Prior art date
Links
- -1 Monocyclic pyridine derivative Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002393 azetidinyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención describe un compuesto representado por la siguiente fórmula (IA) o una sal farmacéuticamente aceptable del mismo: (ver Fórmula) en donde n representa 0 a 2; A representa un grupo arileno o un grupo heteroarileno; G representa un enlace simple, un átomo de oxígeno o -CH2-; E representa un heterociclo no aromático que contiene nitrógeno; R1 representa un grupo alcoxi, un grupo alcoxi alcoxi o similares; R2 representa un átomo de hidrógeno, un átomo de halógeno, un grupo hidroxilo, un grupo alquilo, un grupo hidroxialquilo, un grupo heterocíclico no aromático que contiene nitrógeno o similares; y R3 representa un átomo de hidrógeno, un grupo alquilo, un grupo alcoxi o similares, y R4 representa un grupo alquilo C1-6, con la condición de que cuando E representa un anillo de azetidina y R2 o R3 está presente en un átomo de nitrógeno en el anillo de azetidina, el R2 o R3 no representa un átomo de hidrógeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766922P | 2013-02-20 | 2013-02-20 | |
| PCT/JP2014/053819 WO2014129477A1 (ja) | 2013-02-20 | 2014-02-18 | 単環ピリジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015010698A MX2015010698A (es) | 2016-04-11 |
| MX361870B true MX361870B (es) | 2018-12-18 |
Family
ID=51351646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010698A MX361870B (es) | 2013-02-20 | 2014-02-18 | Derivado de piridina monociclico. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8933099B2 (es) |
| EP (1) | EP2960238B1 (es) |
| JP (2) | JP5600229B1 (es) |
| KR (1) | KR102050128B1 (es) |
| CN (1) | CN105073730B (es) |
| AR (1) | AR094812A1 (es) |
| AU (1) | AU2014219811B2 (es) |
| BR (1) | BR112015019790B1 (es) |
| CA (1) | CA2901585C (es) |
| CL (1) | CL2015002311A1 (es) |
| CY (1) | CY1119220T1 (es) |
| DK (1) | DK2960238T3 (es) |
| ES (1) | ES2628495T3 (es) |
| HR (1) | HRP20170873T1 (es) |
| HU (1) | HUE032931T2 (es) |
| IL (1) | IL240623B (es) |
| JO (1) | JO3261B1 (es) |
| LT (1) | LT2960238T (es) |
| ME (1) | ME02755B (es) |
| MX (1) | MX361870B (es) |
| MY (1) | MY178760A (es) |
| NZ (1) | NZ711101A (es) |
| PE (1) | PE20151509A1 (es) |
| PH (1) | PH12015501813A1 (es) |
| PL (1) | PL2960238T3 (es) |
| PT (1) | PT2960238T (es) |
| RS (1) | RS56064B1 (es) |
| RU (1) | RU2645352C2 (es) |
| SG (1) | SG11201506488WA (es) |
| SI (1) | SI2960238T1 (es) |
| SM (1) | SMT201700288T1 (es) |
| TW (4) | TWI672140B (es) |
| UA (1) | UA116794C2 (es) |
| WO (1) | WO2014129477A1 (es) |
| ZA (1) | ZA201505941B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017002268B1 (pt) * | 2014-08-18 | 2022-11-08 | Eisai R&D Management Co., Ltd | Sal de derivado de piridina monocíclica e cristal do mesmo |
| RU2712222C2 (ru) * | 2015-03-25 | 2020-01-27 | Нэшнл Кэнсер Сентер | Терапевтическое средство против рака желчных протоков |
| WO2017104739A1 (ja) | 2015-12-17 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳がん治療剤 |
| CN107098884A (zh) * | 2016-02-19 | 2017-08-29 | 中国科学院上海药物研究所 | 一类取代的氨基吡啶类化合物及其制备和用途 |
| JP2020536846A (ja) * | 2017-10-12 | 2020-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ選択的チロシンキナーゼ阻害剤を含む医薬組成物 |
| BR112020017922A2 (pt) | 2018-03-28 | 2020-12-22 | Eisai R&D Management Co., Ltd. | Agente terapêutico para carcinoma hepatocelular |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021255084A1 (en) * | 2020-04-17 | 2022-12-08 | Eisai R&D Management Co., Ltd. | Breast cancer therapeutic agent |
| KR20230047056A (ko) | 2020-07-31 | 2023-04-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 유방암 치료제 |
| TW202233185A (zh) | 2020-10-28 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | 腫瘤治療用醫藥組合物 |
| JP2023099776A (ja) * | 2021-08-31 | 2023-07-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 単環ピリジン誘導体の合成中間体の製造方法 |
| JP2023099778A (ja) * | 2021-08-31 | 2023-07-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 単環ピリジン誘導体の製造方法 |
| EP4361143A4 (en) * | 2021-08-31 | 2025-05-28 | Eisai R&D Management Co., Ltd. | Process for the preparation of a monocyclic pyridine derivative |
| TW202328098A (zh) | 2021-08-31 | 2023-07-16 | 日商衛材R&D企管股份有限公司 | 單環吡啶衍生物的合成中間體之製造方法 |
| CA3244743A1 (en) * | 2022-03-18 | 2025-06-13 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | SALT OF A SIX-LINK AMINO-SUBSTITUTE NITRIC HETEROCYCLIC COMPOUND, CRYSTALLINE FORM THEREIN, CORRESPONDING PREPARATION PROCESS AND ASSOCIATED USE |
| CN120021412A (zh) * | 2023-09-18 | 2025-05-20 | 上海润石医药科技有限公司 | 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10006139A1 (de) * | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| US6949585B2 (en) | 2001-04-03 | 2005-09-27 | Eisai Co., Ltd. | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2004020434A1 (ja) * | 2002-08-30 | 2004-03-11 | Eisai Co., Ltd. | 含窒素芳香環誘導体 |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| CN100497339C (zh) | 2003-04-10 | 2009-06-10 | 霍夫曼-拉罗奇有限公司 | 嘧啶并化合物 |
| US20050256154A1 (en) | 2004-05-04 | 2005-11-17 | Kin-Chun Luk | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| FR2883286B1 (fr) | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
| NZ563692A (en) * | 2005-05-23 | 2011-04-29 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| MEP3808A (xx) | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1891955A1 (en) | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| MX2009006704A (es) | 2006-12-22 | 2009-06-30 | Astex Therapeutics Ltd | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. |
| MX2009006706A (es) | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. |
| WO2009001070A1 (en) | 2007-06-25 | 2008-12-31 | Qinetiq Limited | Heater suitable for use in a preconcentrator device |
| WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| WO2009056886A1 (en) | 2007-11-01 | 2009-05-07 | Astrazeneca Ab | Pyrimidine derivatives and their use as modulators of fgfr activity |
| WO2009076660A2 (en) * | 2007-12-13 | 2009-06-18 | Tyratech, Inc. | Organic absorbent material and uses thereof |
| CL2008003675A1 (es) * | 2007-12-13 | 2009-03-20 | Wyeth Corp | Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide. |
| MY155535A (en) | 2008-05-23 | 2015-10-30 | Novartis Ag | Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2009153592A1 (en) | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
| CA2748491C (en) | 2008-12-30 | 2019-08-06 | Arqule, Inc. | Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds |
| CA2748276A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted pyrazolo [3, 4-b] pyridine compounds |
| EP2379556A1 (en) | 2008-12-30 | 2011-10-26 | ArQule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| US9002427B2 (en) | 2009-03-30 | 2015-04-07 | Lifewave Biomedical, Inc. | Apparatus and method for continuous noninvasive measurement of respiratory function and events |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| FR2947546B1 (fr) | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
| EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| PT2471786E (pt) | 2009-08-07 | 2016-03-04 | Hoffmann La Roche | Derivado de aminopirazol |
| IN2012DN03180A (es) | 2009-10-30 | 2015-09-25 | Novartis Ag | |
| AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| WO2013108809A1 (ja) | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | ３，５－二置換ベンゼンアルキニル化合物及びその塩 |
| EP2821402B1 (en) | 2012-02-28 | 2019-08-21 | Astellas Pharma Inc. | Nitrogen-containing aromatic heterocyclic compound |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
| WO2014048878A1 (en) | 2012-09-26 | 2014-04-03 | Evotec (Uk) Ltd. | Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia |
| SG11201502455TA (en) | 2012-09-27 | 2015-05-28 | Chugai Pharmaceutical Co Ltd | Fgfr3 fusion gene and pharmaceutical drug targeting same |
| TWI628176B (zh) | 2013-04-04 | 2018-07-01 | 奧利安公司 | 蛋白質激酶抑制劑 |
-
2014
- 2014-02-17 AR ARP140100495A patent/AR094812A1/es active IP Right Grant
- 2014-02-18 UA UAA201508149A patent/UA116794C2/uk unknown
- 2014-02-18 SG SG11201506488WA patent/SG11201506488WA/en unknown
- 2014-02-18 PT PT147542948T patent/PT2960238T/pt unknown
- 2014-02-18 ME MEP-2017-130A patent/ME02755B/me unknown
- 2014-02-18 SM SM20170288T patent/SMT201700288T1/it unknown
- 2014-02-18 TW TW107134529A patent/TWI672140B/zh active
- 2014-02-18 TW TW107134526A patent/TWI672139B/zh active
- 2014-02-18 EP EP14754294.8A patent/EP2960238B1/en active Active
- 2014-02-18 CA CA2901585A patent/CA2901585C/en active Active
- 2014-02-18 PE PE2015001748A patent/PE20151509A1/es active IP Right Grant
- 2014-02-18 LT LTEP14754294.8T patent/LT2960238T/lt unknown
- 2014-02-18 RU RU2015134558A patent/RU2645352C2/ru active
- 2014-02-18 AU AU2014219811A patent/AU2014219811B2/en active Active
- 2014-02-18 HR HRP20170873TT patent/HRP20170873T1/hr unknown
- 2014-02-18 PL PL14754294T patent/PL2960238T3/pl unknown
- 2014-02-18 TW TW103105419A patent/TWI641602B/zh active
- 2014-02-18 CN CN201480009370.XA patent/CN105073730B/zh active Active
- 2014-02-18 ES ES14754294.8T patent/ES2628495T3/es active Active
- 2014-02-18 JP JP2014526292A patent/JP5600229B1/ja active Active
- 2014-02-18 HU HUE14754294A patent/HUE032931T2/en unknown
- 2014-02-18 JO JOP/2014/0039A patent/JO3261B1/ar active
- 2014-02-18 TW TW107134522A patent/TWI672296B/zh active
- 2014-02-18 SI SI201430247A patent/SI2960238T1/sl unknown
- 2014-02-18 DK DK14754294.8T patent/DK2960238T3/en active
- 2014-02-18 MY MYPI2015702696A patent/MY178760A/en unknown
- 2014-02-18 WO PCT/JP2014/053819 patent/WO2014129477A1/ja not_active Ceased
- 2014-02-18 RS RS20170596A patent/RS56064B1/sr unknown
- 2014-02-18 KR KR1020157022252A patent/KR102050128B1/ko active Active
- 2014-02-18 NZ NZ711101A patent/NZ711101A/en unknown
- 2014-02-18 MX MX2015010698A patent/MX361870B/es active IP Right Grant
- 2014-02-18 BR BR112015019790-6A patent/BR112015019790B1/pt active IP Right Grant
- 2014-02-19 US US14/183,864 patent/US8933099B2/en active Active
- 2014-08-14 JP JP2014165311A patent/JP2014237707A/ja active Pending
-
2015
- 2015-08-17 IL IL240623A patent/IL240623B/en active IP Right Grant
- 2015-08-18 CL CL2015002311A patent/CL2015002311A1/es unknown
- 2015-08-18 PH PH12015501813A patent/PH12015501813A1/en unknown
- 2015-08-18 ZA ZA2015/05941A patent/ZA201505941B/en unknown
-
2017
- 2017-06-15 CY CY20171100631T patent/CY1119220T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501813A1 (en) | Monocyclic pyridine derivative | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| CA2875877C (en) | Syk inhibitors | |
| PH12015500209A1 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
| IN2014MN01897A (es) | ||
| MX365376B (es) | Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo -8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(pr op-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4] triazina-1-carboxamida. | |
| PH12014501719B1 (en) | Pyridone derivatives | |
| PH12015501993A1 (en) | Pyrazole-amide compound and medicinal uses therefor | |
| MX2017005158A (es) | Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk). | |
| PH12015502178A1 (en) | Pyridinylpyrazoloquinoline compound | |
| WO2014197345A3 (en) | Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | |
| PH12019501391A1 (en) | Novel compound and pharmacologically acceptable salt thereof | |
| PH12015501146A1 (en) | Hydantoin derivative | |
| WO2014128228A3 (de) | Medikament | |
| MX2012002529A (es) | Agente terapeutico para trastornos de ansiedad. | |
| MY176508A (en) | Anti-enterovirus 71 thiadiazolidine derivative | |
| IN2012DN01234A (es) | ||
| MX358151B (es) | Derivado de sitaxentan. | |
| MX355654B (es) | Derivado de paroxetina. | |
| PH12015501056A1 (en) | 2-pyridone compound | |
| MX362994B (es) | Preparacion farmaceutica que comprende un derivado de aminopirazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |